These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25803504)

  • 21. Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease.
    Ogata H; Watanabe M; Matsui T; Hase H; Okayasu M; Tsuchiya T; Shinmura Y; Hibi T
    J Crohns Colitis; 2016 Sep; 10(9):1033-41. PubMed ID: 26961546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
    Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.
    Plevris N; Lyons M; Jenkinson PW; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Shand AG; Din S; Arnott ID; Jones GR; Lees CW
    Inflamm Bowel Dis; 2019 May; 25(6):1036-1043. PubMed ID: 30335139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1044-55. PubMed ID: 25185992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease.
    Chalhoub JM; Rimmani HH; Gumaste VV; Sharara AI
    Inflamm Bowel Dis; 2017 Aug; 23(8):1316-1327. PubMed ID: 28719541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study.
    Orlando A; Renna S; Mocciaro F; Cappello M; Giunta M; Mendolaro M; Mazza M; Rizzuto G; Orlando E; Affronti M; Dimarco M; Di Mitri R; Craxì A; Cottone M
    Dig Liver Dis; 2016 Nov; 48(11):1314-1317. PubMed ID: 27578212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients.
    Bultman E; de Haar C; van Liere-Baron A; Verhoog H; West RL; Kuipers EJ; Zelinkova Z; van der Woude CJ
    Aliment Pharmacol Ther; 2012 Feb; 35(3):335-41. PubMed ID: 22191671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
    Panaccione R; Löfberg R; Rutgeerts P; Sandborn WJ; Schreiber S; Berg S; Maa JF; Petersson J; Robinson AM; Colombel JF
    J Crohns Colitis; 2019 May; 13(6):725-734. PubMed ID: 30753371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
    Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Adalimumab for Paediatric Crohn's Disease: A Systematic Review.
    Dziechciarz P; Horvath A; Kierkuś J
    J Crohns Colitis; 2016 Oct; 10(10):1237-44. PubMed ID: 26995184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
    Loftus EV; Reinisch W; Panaccione R; Berg S; Alperovich G; Bereswill M; Kalabic J; Petersson J; Thakkar R; Robinson AM; D'Haens G
    Inflamm Bowel Dis; 2019 Aug; 25(9):1522-1531. PubMed ID: 30753510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.
    Takeshima F; Yoshikawa D; Higashi S; Morisaki T; Oda H; Ikeda M; Machida H; Matsushima K; Minami H; Akazawa Y; Yamaguchi N; Ohnita K; Isomoto H; Ueno M; Nakao K
    BMC Gastroenterol; 2016 Jul; 16(1):82. PubMed ID: 27472988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.